Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous induced islet body is an experimental cell therapy being developed by Allife Medical Science and Technology Co., Ltd. for the treatment of type 1 diabetes mellitus. The therapy involves the generation of islet-like clusters (islet bodies) from a patient's own cells, which are then transplanted back into the patient, specifically under the diaphragm in clinical trial protocols. This autologous approach is designed to restore endogenous insulin production and glycemic control while potentially avoiding the immune rejection and the need for chronic immunosuppression typically associated with allogeneic islet transplantation. The therapy is currently being evaluated in early-stage clinical trials to assess its safety and efficacy in adults with type 1 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous induced islet body.